The Boston Course in Obesity Medicine 2023 (Videos)

Opportunities for the successful management of obesity and its complications are evolving rapidly, with new therapies, clinical practice guidelines and models of care emerging every few months.
To help clinicians, policymakers, researchers and other members of the obesity care community keep up with exciting changes in the obesity science and clinical care, the Boston Course in Obesity Medicine is offering a professional education program updated for 2023.

The past year has been an incredible one for the advancement of obesity science and clinical practice. To name a few of the highlights that will be discussed in this year’s program:

Report of SURMOUNT-1 study, the first phase 3 study of tirzepatide treatment for obesity, which showed up to an average 22% weight loss
Report of the STEP TEENS study of semaglutide 2.4 mg weekly for the treatment of obesity in adolescents, which showed an average of 17% weight loss
FDA approval of semaglutide 2.4 mg weekly for the treatment of obesity in adolescents
Publication of new American Academy of Pediatrics clinical practice guidelines for the treatment of obesity in children and adolescents
Completion of the SELECT study of the effect of semaglutide 2.4 mg weekly on cardiovascular outcomes in patients with obesity without diabetes
Publication of new Institute for Clinical and Economic Review report of the utility and cost-effectiveness of anti-obesity medications
New studies revealing the mechanisms of the body’s resistance to weight loss by calorie reduction alone, and demonstrating that GLP-1 receptor agonists block this resistance
New studies of the adverse effects of highly processed foods
New studies demonstrating the benefits – and limitations – of timed feeding and intermittent fasting
New studies describing the many negative clinical and psychosocial effects and manifestations of weight-related bias, stigma and discriminationPublication of new Canadian clinical practice guidelines for obesity evaluation and management
Report of the one-year phase 2 trial of resmetirom, which showed resolution of NASH and improvement in liver fibrosis
Publication of multiple new clinical practice guidelines for the evaluation and management of patients with NAFLD and NASH
Landmark report of long-term cancer outcomes after bariatric surgery, revealing substantial improvement in cancer incidence and mortality
Report of the first data demonstrating that metabolic and bariatric surgery improves markers of kidney disease
New studies revealing effective approaches to optimizing the benefits and safety of metabolic and bariatric surgery
Publication of new clinical practice guidelines for the selection and use of metabolic and bariatric surgery
New studies demonstrating substantial benefit of endoscopic approaches to treating obesity, diabetes and NAFLD
New studies demonstrating the unique benefits of combination and multimodal treatment of obesity
Development of new models for more efficient organization and dissemination of effective obesity care
Emerging collaborative efforts to substantially improve equitable patient access to effective obesity care
Emergence of a new cadre of start-up companies aiming to streamline access to effective obesity care
Increasing payer and policymaker attention to the substantial clinical and economic benefit of treating obesity effectively as a means of decreasing the number and severity of its medical complications – a first step in improving reimbursement for obesity treatment

Program :
Obesity Medicine Board Review
Obesity Treatment 2023